1047 related articles for article (PubMed ID: 33807957)
1. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
[TBL] [Abstract][Full Text] [Related]
2. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.
Eliakim-Raz N; Leibovici-Weisman Y; Stemmer A; Ness A; Awwad M; Ghantous N; Stemmer SM
JAMA; 2021 Dec; 326(21):2203-2204. PubMed ID: 34739043
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
4. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
5. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
[TBL] [Abstract][Full Text] [Related]
6. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
7. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
9. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.
Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
14. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
15. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
18. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
19. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
20. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
